June 8, 2020 / 8:18 PM / a month ago

Global Blood Therapeutics to seek to expand label for sickle cell treatment

June 8 (Reuters) - Global Blood Therapeutics Inc said on Monday it plans to ask U.S. regulators to greenlight the use of its sickle cell treatment, Oxbryta, in children between ages 4 and 11, expanding on an earlier approval for patients 12 and over.

The South San Francisco, California-based company recently met with the U.S. Food and Drug Administration and plans to submit a formal application for an expanded approval next year, it said in a statement. The company is continuing to collect data supporting Oxbryta's safety and effectiveness in children between 4 and 11 but existing data is strong, Chief Executive Ted Love told Reuters in an interview. (Reporting by Carl O'Donnell Editing by Leslie Adler)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below